Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease

J Clin Transl Hepatol. 2020 Mar 28;8(1):87-99. doi: 10.14218/JCTH.2019.00035. Epub 2019 Dec 11.

Abstract

Gut microbiota has been demonstrated to have a significant impact on the initiation, progression and development of complications associated with multiple liver diseases. Notably, nonalcoholic fatty liver diseases, including nonalcoholic steatohepatitis and cirrhosis, severe alcoholic hepatitis, primary sclerosing cholangitis and hepatic encephalopathy, have strong links to dysbiosis - or a pathobiological change in the microbiota. In this review, we provide clear and concise discussions on the human gut microbiota, methods of identifying gut microbiota and its functionality, liver diseases that are affected by the gut microbiota, including novel associations under research, and provide current evidence on the modulation of gut microbiota and its effects on specific liver disease conditions.

Keywords: Cirrhosis; Illumina; Metagenomics; Microbiome; NGS.

Publication types

  • Review